Susan G. Komen Breast Cancer Foundation

Susan G. Komen Breast Cancer Foundation

Nancy G. Brinker established the Susan G. Komen Breast Cancer Foundation in 1982, two years after her sister Suzy died of breast cancer at age 36. What began as a living-room promise in Peoria, Illinois, grew into the world's largest breast cancer organization, headquartered in Dallas and built on a dual structure of community fundraising affiliates and a centralized research-granting engine. The foundation's wealth originates entirely from philanthropic donations, corporate sponsorships, and fundraising events — most visibly the Race for the Cure series, which pioneered cause-marketing at scale when Brinker convinced corporations to attach their brands to a women's health cause in the 1980s. The foundation deploys capital across three asset classes: research grants to academic and medical institutions, community health programs delivered through a national affiliate network, and a diversified investment portfolio managed for long-term endowment growth. The research program has backed breakthroughs including early work on the BRCA1 gene and trastuzumab, which established the foundation as a significant non-governmental funder of translational science. Community health deployment covers screening, patient navigation, and financial assistance programs in over 30 US states. The foundation's investment portfolio, overseen by CFO Ria Williams, operates as a traditional endowment — generating returns to fund operations and grants while preserving intergenerational capital for the mission. The foundation also launched a Breast Cancer Crypto Fund to accept digital-asset donations, signaling an adaptive fundraising posture. Komen's governance structure separates fiduciary oversight from scientific direction. Ed Dandridge, a former executive at AIG and Marsh & McLennan, chairs the board. An independent Scientific Advisory Board and a group of 60 Komen Scholars — senior scientists and clinicians — lead the peer-review grantmaking process, insulating allocation decisions from fundraising pressures. Former CEO Paula Schneider served from 2017 to 2025, overseeing a period of rebuilding after a 2012 controversy over Planned Parenthood grant funding tested the foundation's political resilience. The foundation maintains a strategic alliance with the Blackstone Charitable Foundation, which serves as presenting sponsor for events including the Band As One Nashville concert, reflecting a deliberate institutional-partnership model rather than purely grassroots fundraising. The foundation's structural differentiator is its hybrid identity: it is simultaneously a grassroots advocacy movement, a major medical-research funder, and an institutional endowment. Unlike general-purpose health foundations, Komen concentrates entirely on a single disease, which concentrates its investment committee's risk and its scientific advisors' expertise. That narrow mandate creates unusual leverage — Komen can fund high-risk early-stage breast cancer research that NIH grant mechanisms may bypass — but it also means the foundation's financial health is unusually correlated with public sentiment toward a single cause.